Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

Lophos Pharmaceuticals announces company is now trading on the CSE under the ticker MESC

Lophos Pharmaceuticals

Lophos Pharmaceuticals CEO Claire Stawnyczy joined Steve Darling from Proactive to share the news that the company which specializes in the cultivation, research, and sale of Lophophora williamsii or peyote cactus has achieved significant milestones. Lophos Pharma has commenced trading on the Canadian Securities Exchange (CSE) under the ticker symbol "MESC." This development marks a significant step for the company in terms of visibility and accessibility to investors. The company has successfully obtained a Controlled Substances Dealers License from Health Canada. This license empowers Lophos Pharma to engage in various activities related to controlled substances, including possession, production, sale/provision, sending, transportation, and delivery. The controlled substances covered by this license include mescaline, psilocin, and psilocybin. Lophos Pharma has entered into a strategic partnership with KGK Science to explore potential pathways to market sustainably grown, peyote-derived natural health products. While peyote itself is legally recognized in Canada, mescaline—the psychoactive compound derived from the peyote cactus—remains classified as a Schedule 3 controlled substance. These developments underscore Lophos Pharma's commitment to advancing its unique position in the emerging market of natural health products derived from peyote. The company's ability to obtain a Controlled Substances Dealers License is particularly noteworthy, as it positions Lophos Pharma to engage in research, production, and distribution of controlled substances in compliance with Canadian regulations. As Lophos Pharma continues its work in researching and developing peyote-derived products, its collaboration with KGK Science represents a key partnership to explore the potential for sustainable and legal market opportunities in this evolving sector. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

September 22, 2023 01:34 PM Eastern Daylight Time

Video

How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space

COMPASS Pathways

By Faith Ashmore, Benzinga Artificial Intelligence (AI) is rapidly penetrating a number of different sectors, including healthcare. The use of AI in mental health has opened up the possibility of new avenues of care, potentially allowing for more efficient diagnosis, treatment and patient care. Machine learning algorithms can analyze vast amounts of data – including patient medical records, genetic information and environmental factors – to potentially identify patterns and predict disorders. Clinicians can also benefit from more accurate and timely diagnoses based on objective digital signals. COMPASS Pathways (NASDAQ: CMPS) is currently developing AI-informed digital systems to assist an investigational treatment for mental health conditions, including treatment-resistant depression (TRD), anorexia nervosa and post–traumatic stress disorder (PTSD). The company is best known for its investigational psilocybin treatment and its R&D focus on mental health conditions. Its goal is to develop new and more effective treatment options for individuals with treatment-resistant depression and other difficult-to-treat mental health conditions. The company’s innovative approach has already yielded promising results, and they received FDA Breakthrough Therapy designation in the U.S. and Innovative Licensing and Access Pathway designation in the U.K. for their investigational COMP360 psilocybin treatment. In late 2021, COMPASS Pathways announced the completion of a randomized, controlled double-blind phase 2b study of COMP360 psilocybin treatment involving 233 patients with TRD in 22 sites across Europe and North America. However, the company believes that drug innovation alone is not enough to improve mental health care. In addition to COMP360 and to better support the drug, COMPASS Pathways has developed three digital tools to help support patients and therapists to ensure the best possible treatment. While these tools will be used in tandem with the COMP360 treatment, the tools were built to be scalable and revolutionize the treatment of mental health disorders. Therapist COMPanion is a web-based portal that supports therapists through all phases of patient care. Psilocybin administration is relatively new to providers so Therapist COMPanion acts as a tool for the provider to ensure that treatment is conducted in the right way. myPathfinder is a patient-facing app that provides guidance throughout COMP360. The psilocybin treatment is grouped into three phases: preparation, administration and integration. COMPASS Pathways was built on the belief that patients deserve better care, especially patients who have been underserved and felt overlooked by the system after being diagnosed as treatment-resistant. This platform is an essential component of taking better care of the patient and ensuring they have the tools to understand their treatment and psilocybin experience. However, the company’s most expansive digital tool is Chanterelle, an AI and analytics infrastructure that can be used for continuous optimization throughout treatment, as well as data collection to help expand a deeper understanding of treatment-resistant disorders. The program records sessions with the patients, with their consent, and can glean a better understanding of success rates using AI and natural language processing. Chanterelle uses the BART large language model which denotes the valence and arousal of the participant and therapist to assess the emotional tenor of the conversation and to better understand if treatment is succeeding. Chanterelle’s application could go beyond COMP360 and was designed to be scalable. The company is working to provide a more concrete and evidence-based way of measuring the success of treatment. While COMPASS Pathways is not the only mental healthcare company to bridge the gap between AI and care, the company’s ability to design platforms that can be used for a variety of disorders sets it apart from competitors like MindMed and Medtronic. Featured photo by Steve Johnson on Unsplash Company BioCOMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). We have commenced a phase 3 clinical program of COMP 360 psilocybin therapy in TRD, the largest randomised, controlled, double-blind psilocybin therapy clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also conducting phase 2 clinical studies of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the United States. Our vision is a world of mental wellbeing. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Stephen Schultz stephen.schultz@compasspathways.com

September 22, 2023 08:30 AM Eastern Daylight Time

Comcast Donates Free WiFi Access to Four Nonprofits in the Twin Cities to Help Increase Digital Opportunities in the Region

Comcast Twin Cities

Comcast today announced the opening of four new Lift Zones in the Twin Cities to provide free WiFi access to families across the area. Furthering the company’s deep and longstanding commitment to advancing equity and opportunity, our new Lift Zones at the International Institute, Every Third Saturday, Al Maa’uun, and GMCC will support digital access and adoption through tech training and career building. The new Lift Zone at International Institute will also receive 250 new laptops and two privacy pods, which will be used for virtual job interviews and telehealth appointments, as needed by clients. Comcast’s Lift Zones program provides free WiFi, powered by Comcast Business, to enable students, seniors, families, and community members to get online and fully participate in the digital economy. With these four new locations, Comcast now offers over 115 Lift Zones throughout the Twin Cities. Comcast’s investments in the four partner organizations will help increase college and career readiness, especially among underserved youth; connect workers to opportunities; provide upskilling for adult learners and those already in the workforce; and close the skills – particularly digital skills – gap. “The tasks of starting a new life in a new country can be overwhelming for refugees and immigrants when they arrive. Digital literacy and lack of reliable internet access can get in the way of applying for work, participating in classes or accessing community services,” said Jane Graupman, Executive Director, International Institute of Minnesota. “Thanks to Comcast and this Lift Zone partnership, we can make this time a little easier for New Americans who contribute so much to our community.” “Helping to close the digital divide and address digital equity remain top priorities here in the Twin Cities,” said Makram El-Amin, Executive Director from Al Maa’uun. “Our city and our region have become even more dependent on broadband to learn, find work and healthcare services and so many other aspects of our daily life. Comcast’s new Lift Zones will create endless opportunities for so many individuals, families, and seniors in our community.” “We’re proud to partner with these four wonderful organizations to launch new Lift Zones to advance digital equity and workforce readiness in our most vulnerable neighborhoods,” said Kalyn Hove, Regional Senior Vice President, Comcast Midwest. “Our continued partnership with our community partners will equip individuals, families and seniors with the tools, skills and resources they need to achieve their goals.” “Helping our communities achieve digital equity is in our DNA at Comcast,” said Broderick Johnson, EVP, Public Policy, and EVP, Digital Equity, Comcast Corporation. “We’re thrilled to partner with the International Institute, Every Third Saturday, Al Maa’uun, and GMCC on our next installation of Lift Zones in the Twin Cities and to work with partners who share our same goals of closing the digital divide.” Today’s announcement is part of Project UP, Comcast’s $1 billion commitment to reach millions of people with the tools, resources, and skills needed to succeed in a digital world. Comcast’s Lift Zones complement Internet Essentials, which since 2011, has helped connect more than 10 million low-income people to the Internet at home. In Minnesota, the program has connected more than 416,000 Minnesotans. Comcast also participates in the Affordable Connectivity Program (ACP), which provides qualifying households with a $30 per month credit, or $75 per month on Tribal lands, toward their Internet and mobile services. New and existing Xfinity Internet or Internet Essentials customers can learn more about the program and sign up by visiting: https://www.xfinity.com/learn/internet-service/acp/free-internet. About Comcast Corporation Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company. From the connectivity and platforms we provide, to the content and experiences we create, our businesses reach hundreds of millions of customers, viewers, and guests worldwide. We deliver world-class broadband, wireless, and video through Xfinity, Comcast Business, and Sky; produce, distribute, and stream leading entertainment, sports, and news through brands including NBC, Telemundo, Universal, Peacock, and Sky; and bring incredible theme parks and attractions to life through Universal Destinations & Experiences. Visit www.comcastcorporation.com for more information. Contact Details Comcast Corporation Jill Hornbacher +1 651-425-1695 Jill_Hornbacher@comcast.com Company Website https://midwest.comcast.com

September 21, 2023 10:00 AM Central Daylight Time

Synairgen looking beyond COVID in fight against respiratory illness

Synairgen PLC

Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden speaks to Thomas Warner from Proactive London about the company's ongoing efforts to develop what he describes as a "drug to help patients handle respiratory viruses." He explains that work on the drug long predates the COVID pandemic and has intensified since, but is careful to emphasise that the intention of Synairgen is to develop a respiratory drug that can be of use to patients with other respiratory conditions as well. He notes the importance of looking beyond COVID-19, given the unpredictability of its media presence and its potential long-term existence alongside other viruses. Marsden discusses their past Sprinter trial and the need for targeted future clinical trials. Utilising technologies and data that emerged during the pandemic, Synairgen plans to identify patients most likely to deteriorate due to the virus. This strategic approach aims to conduct faster trials with a higher chance of success. Marsden concluded that as they refine patient selection for upcoming trials, they'll announce results and commence the next clinical trial phase. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 21, 2023 08:40 AM Eastern Daylight Time

Video

Genflow Biosciences reports positive news from Belgium

Genflow Biosciences PLC

Genflow Biosciences PLC (LSE:GENF, OTC:GENFF) CEO Dr. Eric Leire speaks to Thomas Warner from Proactive after the longevity-focused UK based biotech company released a company update highlighting a successful first regulatory interaction with the Federal Agency for Medicines and Health Products (FAHMP) in Belgium. Dr Leire explains that the news helps pave the way for clinical trials and was particularly noteworthy because of the agency's recommendation to commence directly with NASH (Non-Alcoholic Steatohepatitis) patients, bypassing the traditional phases. He expects the move to accelerate the proof of concept process and boost the company's valuation. Additionally, a strategic restructuring is underway, aimed at enhancing eligibility for grants, a crucial aspect in mitigating financial risk for early-stage biotech ventures. Dr Leire explains that the move aligns with Genflow's strategy of minimising reliance on venture capital funding and focusing instead on attracting non-dilutive grants. He also draws attention to planned FDA interaction and promising in vivo studies. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 20, 2023 07:10 AM Eastern Daylight Time

Video

BiVictriX Therapeutics "looking really healthy" after positive first half

BiVictriX Therapeutics PLC

BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) founder and CEO Tiffany Thorn speaks to Thomas Warner from Proactive after the UK-based drug discovery and development company released its interim results for the six months to 30 June 2023. Thorn gives her take on how the business performed during the reporting period, highlighting the nomination of a clinical candidate for the lead programme, BVX001 as well as progress on BVX002 and BVX003. BiVictriX also bolstered its financial position with a successful fundraise, raising over £2 million, supplemented by a £0.5 million R&D tax credit claim. Thorn emphasises the robust financial position of the company, saying that the runway "is looking really healthy... we've got sufficient funds to carry out our near-term objectives." She also mentions growth in the team itself, as it sharpens its focus on the partnering opportunities that she describes as the company's key focus. Looking ahead, the focus lies on advancing program readiness for clinical use, scaling up drug manufacturing, and forging those key business development relationships. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 20, 2023 03:00 AM Eastern Daylight Time

Video

Scancell CEO hails "exciting" high response rate to melanoma treatment

Scancell Holdings PLC

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the initial phase of the clinical stage biopharmaceutical company's Phase 2 SCOPE trial in advanced melanoma. Professor Durrant gives an overview of the findings so far, saying that in the initial 11 patients they have achieved an impressive 82% overall response rate, surpassing the anticipated 70%. This development could be crucial for metastatic melanoma patients, as previous studies reported only a 50% response rate. She adds that the potential to significantly improve outcomes is especially significant given the rising cases, particularly among young women. While further confirmation is needed in a larger cohort, the data's strength suggests promising results in the broader study. Looking ahead, the trial aims to recruit 43 patients, expecting over 27 respondents, with potential adjustments based on the remarkable initial response rate. Professor Durrant also provides an update on Modi1 vaccine and Scancell's antibody platform. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 20, 2023 03:00 AM Eastern Daylight Time

Video

News Release

Tonix Pharmaceuticals releases positive results from Proof-Of-Concept Study on TNX-102 SL

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr Seth Lederman joined Steve Darling from Proactive to share significant news regarding the Phase 2 proof-of-concept PREVAIL study of TNX-102 SL 5.6 mg for the management of fibromyalgia-type Long COVID. Dr Lederman provided an overview of the study's topline results and the implications for future development. Dr Lederman announced that the study showed a robust effect size in improving fatigue, a key symptom of Long COVID. The results also demonstrated consistent activity trending towards improvements across secondary endpoints, including sleep quality, cognitive function, disability, and patient global impression of change. However, Dr Lederman noted that TNX-102 SL did not achieve the pre-specified primary endpoint of improving Long COVID pain intensity scores at Week 14. Despite this, the proposed mechanism of TNX-102 SL, which aims to improve sleep quality, aligns with recent announcements from the National Institutes of Health (NIH) that sleep quality is a target for future clinical trials in Long COVID. Dr Lederman highlighted that there is currently no approved drug for the treatment of Long COVID, making these findings important for potential future treatments. The company's plan is to request an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the possibility of a Phase 3 program. They intend to propose a primary outcome measure using the PROMIS Fatigue scale, which is widely recognized and validated for assessing fatigue across various conditions. Dr Lederman also told Proactive the company is committed to meeting potential increased demand for its Tosymra nasal spray 10 mg following GlaxoSmithKline’s planned discontinuation of Imitrex nasal spray 5 mg and 20 mg products after January 2024. This move by Tonix is to be ready in case of possible drug shortages for patients who suffer from migraines. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

September 19, 2023 01:54 PM Eastern Daylight Time

Video

PathAI Announces Expansion of BioPharma Lab to Provide End-to-End Central Pathology and Histology Services

PathAI

PathAI, a global leader in AI-powered pathology, today announced the expansion of its BioPharma Laboratory Services. Capitalizing on the 30-year history of delivering high quality pathology services in the PathAI Diagnostics clinical laboratory (formerly known as Poplar Healthcare), PathAI offers biopharma partners a comprehensive, GCP/GCLP compliant histology and digital pathology lab to support prospective clinical trials across oncology, liver, and gastrointestinal indications. The lab offers pharmaceutical companies access to unparalleled histological laboratory services and comprehensive operational support, encompassing the full end-to-end tissue processing from kitting and logistics management, tissue processing and staining across H&E, IHC, and special stains; local and remote pathology tapping into PathAI’s network of >500 US board-certified pathologists; and AI-driven analysis from PathAI’s menu of algorithms and clinical trial software. This integrated approach enables the streamlined, proficient, and regulatory-compliant implementation of controlled clinical trials, all within a single facility. PathAI’s BioPharma Lab has a unique combination of capabilities to enable clinical trials where pathology-based endpoints, biomarker classification, and/or superior histology quality are critical to the success of their pharma partners. Over the last two years, the company has already supported Phase 2 clinical trials in NASH, IBD, and breast cancer, as well as oncology neoadjuvant trials. Based on successfully meeting key milestones on quality and turnaround times, PathAI is expanding and scaling its services to new trial indications and partners. The lab adheres to all relevant quality, regulatory, and compliance standards including CAP/CLIA and GCP/GCLP. In addition to full laboratory support for clinical trials, PathAI’s BioPharma Lab supports trials through its AI products and expertise with AI-powered endpoint assessment and patient enrollment. “We don’t just create algorithms, we stay in lock step with our pharma partners to ensure our AI products are integrated into trials appropriately, based on regulatory criteria, to enhance trial quality and efficiency,” said Andy Beck, MD, PhD, CEO of PathAI. The BioPharma Lab’s expertise helps reduce the impact of many challenges associated with clinical trials, including unreliable turnaround times, variable histology, stain or scan/digitization quality, and challenging assessment of histological endpoints. In addition, the lab allows pharma partners the ability to use AI without a heavy lift to implement. The lab offers most major types of instrumentation, with flexible workflows across different scanners, stains, and biopsy types, which improves the quality of clinical trials. Importantly, the services include access to PathAI’s extensive network of over 500 US Board Certified pathologists to perform high quality reading with rapid turnaround time in a cost-effective manner. “During my time running translational sciences in a Top 10 pharma company, I witnessed a strong need for high quality, scalable, and flexible pathology services that can further be combined with the state-of-the-art technology in digital pathology and AI,” said Mike Montalto, PhD, Chief Scientific Officer, of PathAI. “We took a pharma-first approach when establishing this lab and its offerings.” The BioPharma Lab will physically expand in 2024 to allow an increase in sample throughput to accommodate larger scale global phase 3 studies, as well as additional equipment to support a wider range of clinical studies. Learn more about how PathAI’s BioPharma Lab can power your next clinical trial by contacting BD@pathai.com or visiting https://www.pathai.com/clinical-trial-services/. PathAI will be at several upcoming conferences with representatives available to speak about the lab’s capabilities, including ESMO, SCOPE Europe (booth #4), and SCOPE Orlando (booth #206). About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of patient samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

September 19, 2023 10:00 AM Eastern Daylight Time

1 ... 92 93 94 95 96 ... 309